

Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version














Contact Us - Confluence Pharmaceuticals



















Confluence Pharmaceuticals





















				Home
			



				About Us
			



				Pipeline
			



				News
			



				Contact Us
			








For More Information or to Contact Us:

Name *



First



Last





Email *






Comment *














Submit






Confluence Pharmaceuticals LLC351 West 10th StreetBox 528Indianapolis, IN  46202(317) 379-7498



Create a free website

			Powered by 




















✕






Confluence Pharmaceuticals - Home





















Confluence Pharmaceuticals





















				Home
			



				About Us
			



				Pipeline
			



				News
			



				Contact Us
			




Restoring Hope, Unlocking Potential
 Confluence's mission is to advance all research in Autism and Fragile X Syndrome and bring to market a solution that treats core social and communication impairments.  We understand the profound impact of being able to communicate and socially interact has on everyday life.  We want to change the way people think about treating Fragile X and Autism....and how they will administer or direct therapies in the future.   



What We Do
Confluence is developing a novel, clinically-discovered therapeutic  treatment for core social and communication impairments caused by Fragile X Syndrome and Autism Spectrum Disorders. We are targeting important functionality - talking, thinking, social interaction, and self-care.   



Create a free website

			Powered by 




















✕






Confluence Pharmaceuticals - Home





















Confluence Pharmaceuticals





















				Home
			



				About Us
			



				Pipeline
			



				News
			



				Contact Us
			




Restoring Hope, Unlocking Potential
 Confluence's mission is to advance all research in Autism and Fragile X Syndrome and bring to market a solution that treats core social and communication impairments.  We understand the profound impact of being able to communicate and socially interact has on everyday life.  We want to change the way people think about treating Fragile X and Autism....and how they will administer or direct therapies in the future.   



What We Do
Confluence is developing a novel, clinically-discovered therapeutic  treatment for core social and communication impairments caused by Fragile X Syndrome and Autism Spectrum Disorders. We are targeting important functionality - talking, thinking, social interaction, and self-care.   



Create a free website

			Powered by 




















✕






News - Confluence Pharmaceuticals



















Confluence Pharmaceuticals





















				Home
			



				About Us
			



				Pipeline
			



				News
			



				Contact Us
			




In the News
Confluence Pharmaceuticals Signs Co-Development and Marketing Agreement with AOP Orphan Pharmaceuticals for Fragile X DrugPress ReleaseConfluence Receives European Orphan Drug Designation for Fragile X Syndromehttp://ec.europa.eu/health/documents/community-register/html/orphreg.htmNational Fragile X Research Foundation Recognizes Dr. Craig Erickson for Outstanding Research and Clinical Service to Worldwide Fragile X Communityhttp://www.fragilex.org/2014/International-fragile-x-conference/2014-conference-awardConfluence Receives U.S. Orphan Drug Designation for Fragile X Syndromehttp://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?index_Number=392413The John Merck Fund Awards Dr. Erickson $1 Million Research Grant| Acamprosate for FXShttp://www.fragilex.org/2013/foundation/press-release/merck-fundAutism Speaks Funds Dr. Erickson's Research | Acamprosate for ASD with TrailBlazer Awardhttp://www.autismspeaks.org/science/grants/acamprosate-youth-autism-spectrum-disordersVIDEO | Standards for Diagnosing Autism Under Review. NBC News Interviewhttp://today.msnbc.msn.com/id/26184891/vp/47827711#47827711 Bioscience Technology | Fragile X Gene’s Prevalence Suggests Broader Health Riskhttp://www.biosciencetechnology.com/News/2012/06/VIDEO | Study Shows 1 in 88 Have Autism.  Fox59 News Interview with Dr. Craig Ericksonhttp://www.fox59.com/videogallery/69120370/News/VIDEO-Study-Shows-1-in-8-Have-AutismIndianapolis Star Interview |  Rising Star- Dr. Craig Ericksonhttp://www.indystar.com/article/20110417/BUSINESS/304170026/Rising-Star-Dr-Craig-Erickson-autism-specialistDr. Craig Erickson Discusses the Drug Acamprosate for the Treatment of Fragile Xhttp://nfxf.blogspot.com/2011/05/dr-craig-erickson-discusses-drug.htmlArticle & VIDEO |  Indy Doctors Treat Autism With Alcoholism Drughttp://www.theindychannel.com/news/27627926/detail.htmlNCB Affiliate WTHR13 |  New study uses alcoholism treatment for Fragile Xhttp://www.wthr.com/story/14360796/new-study-uses-alcoholism-treatment-for-fragile-x?client



Create a free website

			Powered by 




















✕






About Us - Confluence Pharmaceuticals



















Confluence Pharmaceuticals





















				Home
			



				About Us
			



				Pipeline
			



				News
			



				Contact Us
			




Management Team
                                  Confluence has assembled an experienced management team, Business and Science Advisory Boards, and attracted various other important collaborators to our effort.  The management team's experience spans from the launch of new businesses, through capitalization, commercialization and exit.    Steven L. Johns, President and Founder      Steve Johns has built a reputation as a Visionary Innovator and Leader through a variety of diverse experiences acquired in a number of successful start-ups and early stage companies. His work career includes 10 years in Banking / Financial Management and 15 years in his own business ventures. Steve’s business experience extends in these key areas; Strategic Planning, Building Management Teams, Transforming Business Models, Mergers & Acquisitions, and Capital Formation.  Mr. Johns holds a B.S. degree from the University of Illinois and an M.B.A. from Indiana University.  He currently sits on the board of the Venture Club of Indiana. Dr. Craig A. Erickson, Lead Scientific Advisor & Founder     Dr. Erickson is the Chief of the Fragile X Research and Treatment Center at Cincinnati Children's Hospital Medical Center, Adjunct Assistant Professor of Psychiatry at Indiana University School of Medicine, Former Chief of the Christian Sarkine Autism Treatment Center and Former Chief of Fragile X Research and Treatment Center, Riley Hospital for Children, Indiana University School of Medicine.  He is currently directing several research projects  with patients being treated at Indiana University and is involved with other national Fragile X Syndrome and Autism Spectrum Disorder related research.  Boyd W. Sturdevant, Jr., Chairman and Founder    Boyd Sturdevant, Jr. has been associated with the mental health industry most of his 40 year career.   He developed and recently sold Indiana’s largest freestanding Employee Assistance business and pioneered per-capita mental health managed care programs with employers.  Boyd brings a depth of working knowledge in the areas of commercializing mental health services, engaging mental health advocate/consumer groups, measuring perception of treatment outcomes, and, executives coaching and consultation.  He has served on his national professional board and chaired the State of Indiana Mental Health Advisory Council.  He has a BS from Indiana University and Master of Ministry from Christian Theological Seminary.      Timothy F. Parshall, Vice President of Corporate Affairs Mr. Parshall has over 25 years experience in global healthcare strategy, marketing and business development.  Mr. Parshall has been a Director of Strategic Marketing at both Guidant and Eli Lilly & Company.  He led product marketing and technology acquisition efforts on a national and international level.   His current focus is on the development of start-up and early-stage revenue companies in both the medical device and biotechnology fields.  Mr. Parshall is the founder of Pivotal Strategies—a strategic marketing and business development organization based in Indianapolis, IN.   He has a Bachelors Degree in Pharmacy from the University of Sydney and a Master of Business Administration from the University of New South Wales, Australia.   Dr. Sharon Rosenzweig-Lipson, Vice President of Research  Dr. Rosenzweig-Lipson has over 18 years experience developing compounds for Psychiatric and Neurologic indications in the pharmaceutical industry (American Cyanamid – American Home Products – Wyeth – Pfizer). Sharon has successfully led teams from the earliest exploratory studies through to Phase II Proof of Concept Trials. In 2011, she founded IVS Pharma Consulting LLC to bring her expertise in in screening strategies, in vivo models, translation and early clinical development strategy to the Neuroscience Scientific Community in Pharma, Biotech and Academia.  Kenneth G. Payie, Ph.D., RAC- Director of CM&C    Dr. Ken Payie has almost a decade in the large pharma industry in a variety of research and development positions.  With a background in large and small molecule Chemistry Manufacturing & Controls (CM&C) development, virtual drug development experience, and Six Sigma black belt execution, Dr. Payie has developed a number of large and small molecule CM&C programs in the Candidate Identification to Phase II space for both large pharma and small drug discovery companies.  Dr. Payie has designed and directed drug development programs through outsourcing to Asia, Europe and North American vendors, and dramatically reduced costs to develop assets without compromising Quality. In 2011, Dr. Payie founded KGP-Biotech Consulting LLC to bring his expertise to the scientific and drug development communities.   In addition to his involvement with KGP and Confluence, Dr. Payie has held senior positions at Chorus Europe, Vanthys Pharmaceutical Development and Eli Lilly. 



Business & Scientific Advisory Boards Represented in alphabetical order by last name:
 Leonard Abbeduto, PhD  (SAB emeritus)  Dr. Abbeduto is professor of educational psychology, communicative disorders, and psychology and a director of the internationally recognized MIND institute at University of California, Davis Campus.  He is the former associate director for Behavioral Sciences and director of the University Center for Excellence in Developmental Disabilities at the University of Wisconsin's Waisman Center. He is considered one of the leading scholars investigating the language problems of children with intellectual disabilities, including fragile X syndrome, Down Syndrome, Autism, Language Disorders, and family impacts of these developmental disabilities.  He has published over 80 articles, chapters, and reviews, as well as seven books. His research has been supported by the NIH almost continuously since 1984.  Among his many notable achievements, Abbeduto has received the Charles J. Anderson Professor of Education in 2008, the UW-Madison Kellett Mid-Career Research Award in 2008, the UW-Madison School of Education Distinguished Faculty Achievement Award in 2008, the Emil A. Steiger Distinguished Teaching Award in 1996, and is a Fellow, American Association on Intellectual and Developmental Disabilities, and is a past chair of the Department of Educational Psychology. He is the president-elect of the Academy on Mental Retardation and the co-director of the NIH-funded Gatlinburg Conference on Intellectual and Developmental Disabilities.  Dr. Abbeduto earned his PhD in psychology from the University of Illinois at Chicago in 1982. He completed a postdoctoral fellowship at Vanderbilt University before joining the faculty at the University of Wisconsin-Madison in 1987. Michael Aman, PhD  (SAB) Dr. Michael Aman is a Professor of Psychology and Psychiatry at Ohio State University, where he directs one of eight NIMH Research Units on Pediatric Psychopharmacology. Dr. Aman was a co-developer of the Aberrant Behavior Checklist (ABC) and of the Nisonger Child Behavior Rating Form (NCBRF). The ABC has been used extensively in pharmacological and other research in people with autism spectrum disorders and other developmental disabilities. To date, there are over 275 studies with the ABC, and it has been translated into at least 26 foreign languages. Dr. Aman has over 220 scholarly publications, including two editions of the popular text, Practitioner's Guide to Psychoactive Drugs for Children and Adolescents.  Dr. Aman is on the editorial boards of seven scientific journals. In 2003, Dr. Aman received a Career Scientist Award from the American Academy on Mental Retardation.  Bradley W. Fravel, PhD  (BAB, SAB)Dr. Fravel is a Business Development Manager at the Indiana University Research & Technology Corporation. Brad’s responsibilities include technology evaluation, marketing, intellectual property strategy & management, and technology commercialization.   Having held positions as an Academic and an Industry scientist, he understands the benefits of strong relationships between faculty researchers and the private sector.  Prior to joining the IURTC, Brad taught Chemistry at Butler University and worked with the Butler Business Accelerator.  Brad came to Butler after spending two years in Washington, D.C. evaluating large national and international capital projects as an analyst for the consulting firm, Independent Project Analysis.  Prior to IPA, Brad was a research chemist and project manager for Indianapolis-based Reilly Industries, a global specialty chemicals company.  An Indiana native, Brad earned a Ph.D. in Organic Chemistry from Indiana University after graduating with a Bachelor of Science degree in Chemistry from Southern Methodist University in Dallas, TX.  He also has an M.B.A. in Finance from Butler University. Bryan H. King, M.D. (SAB)    Dr. King is Professor and Vice Chair of Psychiatry and Behavioral Sciences and Director of Child and Adolescent Psychiatry at the University of Washington and Seattle Children’s Hospital. Dr. King’s clinical and research interests have been focused on  psychiatric aspects of developmental disorders, repetitive movements,  and upon the pathogenesis and treatment of behavioral disturbance in  autism. He currently chairs a multi-site psychopharmacology network for the  National Institutes of Health funded STAART (Studies to Advance Autism  Research and Treatment) Centers formed to examine the potential role for  an antidepressant medication in the treatment of children with autism  who have significant problems with repetitive behaviors. He is also Director of the NIH funded UW Autism Center of Excellence and the Seattle Children’s Autism Center.      Dr. King completed his medical training at the Medical College of Wisconsin, and subsequently did his medical internship and psychiatric training at the UCLA Medical Center and Neuropsychiatric Institute. He obtained his clinical and research training in Child and Adolescent Psychiatry at UCLA and at the Merck Neuroscience Research Center in England with sponsorship of the National Institutes of Health.  Dr. King is a co-author on the practice parameters for children and adults with developmental disorders and mental illnesses by the American Academy of Child and Adolescent Psychiatry. He has written extensively in the medical literature relating to this field, and has received lifetime achievement awards from the American Academy of Child and Adolescent Psychiatry, and from the American Psychiatric Association, for his work in the field of Developmental Disabilities. Joseph Muldoon  (BAB) Chief Executive Officer & Board Director- FAST BioMedical                    Mr. Muldoon leverages decades of experience, from technology start-ups to publicly-traded multi-nationals. He has worked with dozens of entrepreneurial companies with roles spanning advisor, investor, and CEO as an Entrepreneur in Residence of the Indiana Venture Center.  His focus is enterprise value creation, culture building and mergers, acquisitions, and exits.  His medical technology experience includes TGX Medical, Vasc-Alert, DynoMed (sold to ChartLogic) Trust Bearer Labs (sold to Verisign), and Geist Pharmaceuticals.  Previously, he was President and CEO of FirstMile Technologies, a start-up broadband provider he led through its sale.  Prior to that, he served as President of Brightpoint North America, a publicly traded Fortune 500 wireless company that grew                     fourfold to $750MM under his leadership. He has also held executive management positions at MacMillan.  He started his career as a CPA in Ernst & Young’s Entrepreneurial Services practice.  Mr. Muldoon has a Bachelor of Science in Business from Indiana University’s Kelley School of Business, where he is a panelist and speaker for multiple MBA programs    Legal, Regulatory and Other Collaborators     Confluence has retained the services of the following professionals to assist in the Company’s legal, regulatory and other affairs.     Mr. Marcus B. Chandler & Martin Zivitz (Legal Advisors)Attorney-at-LawBarnes & Thornburg, LLP11 South Meridian StreetIndianapolis, IN  46204-3535    Mr. Kenneth V. Phelps (Regulatory Advisor)President & CEOCamargo Pharmaceutical Services, LLC9825 Kenwood Road , Suite 203Cincinnati, OH  45242    Mr. David Nelson, PhD (NeuroPharmacology- Discovery & Development)Founder, Council Mountain Pharma ConsultingPhoenix, AZ 



Create a free website

			Powered by 




















✕






Pipeline - Confluence Pharmaceuticals





















Confluence Pharmaceuticals





















				Home
			



				About Us
			



				Pipeline
			



				News
			



				Contact Us
			




Drug Development Pipeline

The pharmacological dynamics of our therapeutic agents match the heterogeneity of these disorders which is in sharp contrast to other drugs that target a single neurochemical mechanism or pathway.  




Create a free website

			Powered by 




















✕






About Us - Confluence Pharmaceuticals



















Confluence Pharmaceuticals





















				Home
			



				About Us
			



				Pipeline
			



				News
			



				Contact Us
			




Management Team
                                  Confluence has assembled an experienced management team, Business and Science Advisory Boards, and attracted various other important collaborators to our effort.  The management team's experience spans from the launch of new businesses, through capitalization, commercialization and exit.    Steven L. Johns, President and Founder      Steve Johns has built a reputation as a Visionary Innovator and Leader through a variety of diverse experiences acquired in a number of successful start-ups and early stage companies. His work career includes 10 years in Banking / Financial Management and 15 years in his own business ventures. Steve’s business experience extends in these key areas; Strategic Planning, Building Management Teams, Transforming Business Models, Mergers & Acquisitions, and Capital Formation.  Mr. Johns holds a B.S. degree from the University of Illinois and an M.B.A. from Indiana University.  He currently sits on the board of the Venture Club of Indiana. Dr. Craig A. Erickson, Lead Scientific Advisor & Founder     Dr. Erickson is the Chief of the Fragile X Research and Treatment Center at Cincinnati Children's Hospital Medical Center, Adjunct Assistant Professor of Psychiatry at Indiana University School of Medicine, Former Chief of the Christian Sarkine Autism Treatment Center and Former Chief of Fragile X Research and Treatment Center, Riley Hospital for Children, Indiana University School of Medicine.  He is currently directing several research projects  with patients being treated at Indiana University and is involved with other national Fragile X Syndrome and Autism Spectrum Disorder related research.  Boyd W. Sturdevant, Jr., Chairman and Founder    Boyd Sturdevant, Jr. has been associated with the mental health industry most of his 40 year career.   He developed and recently sold Indiana’s largest freestanding Employee Assistance business and pioneered per-capita mental health managed care programs with employers.  Boyd brings a depth of working knowledge in the areas of commercializing mental health services, engaging mental health advocate/consumer groups, measuring perception of treatment outcomes, and, executives coaching and consultation.  He has served on his national professional board and chaired the State of Indiana Mental Health Advisory Council.  He has a BS from Indiana University and Master of Ministry from Christian Theological Seminary.      Timothy F. Parshall, Vice President of Corporate Affairs Mr. Parshall has over 25 years experience in global healthcare strategy, marketing and business development.  Mr. Parshall has been a Director of Strategic Marketing at both Guidant and Eli Lilly & Company.  He led product marketing and technology acquisition efforts on a national and international level.   His current focus is on the development of start-up and early-stage revenue companies in both the medical device and biotechnology fields.  Mr. Parshall is the founder of Pivotal Strategies—a strategic marketing and business development organization based in Indianapolis, IN.   He has a Bachelors Degree in Pharmacy from the University of Sydney and a Master of Business Administration from the University of New South Wales, Australia.   Dr. Sharon Rosenzweig-Lipson, Vice President of Research  Dr. Rosenzweig-Lipson has over 18 years experience developing compounds for Psychiatric and Neurologic indications in the pharmaceutical industry (American Cyanamid – American Home Products – Wyeth – Pfizer). Sharon has successfully led teams from the earliest exploratory studies through to Phase II Proof of Concept Trials. In 2011, she founded IVS Pharma Consulting LLC to bring her expertise in in screening strategies, in vivo models, translation and early clinical development strategy to the Neuroscience Scientific Community in Pharma, Biotech and Academia.  Kenneth G. Payie, Ph.D., RAC- Director of CM&C    Dr. Ken Payie has almost a decade in the large pharma industry in a variety of research and development positions.  With a background in large and small molecule Chemistry Manufacturing & Controls (CM&C) development, virtual drug development experience, and Six Sigma black belt execution, Dr. Payie has developed a number of large and small molecule CM&C programs in the Candidate Identification to Phase II space for both large pharma and small drug discovery companies.  Dr. Payie has designed and directed drug development programs through outsourcing to Asia, Europe and North American vendors, and dramatically reduced costs to develop assets without compromising Quality. In 2011, Dr. Payie founded KGP-Biotech Consulting LLC to bring his expertise to the scientific and drug development communities.   In addition to his involvement with KGP and Confluence, Dr. Payie has held senior positions at Chorus Europe, Vanthys Pharmaceutical Development and Eli Lilly. 



Business & Scientific Advisory Boards Represented in alphabetical order by last name:
 Leonard Abbeduto, PhD  (SAB emeritus)  Dr. Abbeduto is professor of educational psychology, communicative disorders, and psychology and a director of the internationally recognized MIND institute at University of California, Davis Campus.  He is the former associate director for Behavioral Sciences and director of the University Center for Excellence in Developmental Disabilities at the University of Wisconsin's Waisman Center. He is considered one of the leading scholars investigating the language problems of children with intellectual disabilities, including fragile X syndrome, Down Syndrome, Autism, Language Disorders, and family impacts of these developmental disabilities.  He has published over 80 articles, chapters, and reviews, as well as seven books. His research has been supported by the NIH almost continuously since 1984.  Among his many notable achievements, Abbeduto has received the Charles J. Anderson Professor of Education in 2008, the UW-Madison Kellett Mid-Career Research Award in 2008, the UW-Madison School of Education Distinguished Faculty Achievement Award in 2008, the Emil A. Steiger Distinguished Teaching Award in 1996, and is a Fellow, American Association on Intellectual and Developmental Disabilities, and is a past chair of the Department of Educational Psychology. He is the president-elect of the Academy on Mental Retardation and the co-director of the NIH-funded Gatlinburg Conference on Intellectual and Developmental Disabilities.  Dr. Abbeduto earned his PhD in psychology from the University of Illinois at Chicago in 1982. He completed a postdoctoral fellowship at Vanderbilt University before joining the faculty at the University of Wisconsin-Madison in 1987. Michael Aman, PhD  (SAB) Dr. Michael Aman is a Professor of Psychology and Psychiatry at Ohio State University, where he directs one of eight NIMH Research Units on Pediatric Psychopharmacology. Dr. Aman was a co-developer of the Aberrant Behavior Checklist (ABC) and of the Nisonger Child Behavior Rating Form (NCBRF). The ABC has been used extensively in pharmacological and other research in people with autism spectrum disorders and other developmental disabilities. To date, there are over 275 studies with the ABC, and it has been translated into at least 26 foreign languages. Dr. Aman has over 220 scholarly publications, including two editions of the popular text, Practitioner's Guide to Psychoactive Drugs for Children and Adolescents.  Dr. Aman is on the editorial boards of seven scientific journals. In 2003, Dr. Aman received a Career Scientist Award from the American Academy on Mental Retardation.  Bradley W. Fravel, PhD  (BAB, SAB)Dr. Fravel is a Business Development Manager at the Indiana University Research & Technology Corporation. Brad’s responsibilities include technology evaluation, marketing, intellectual property strategy & management, and technology commercialization.   Having held positions as an Academic and an Industry scientist, he understands the benefits of strong relationships between faculty researchers and the private sector.  Prior to joining the IURTC, Brad taught Chemistry at Butler University and worked with the Butler Business Accelerator.  Brad came to Butler after spending two years in Washington, D.C. evaluating large national and international capital projects as an analyst for the consulting firm, Independent Project Analysis.  Prior to IPA, Brad was a research chemist and project manager for Indianapolis-based Reilly Industries, a global specialty chemicals company.  An Indiana native, Brad earned a Ph.D. in Organic Chemistry from Indiana University after graduating with a Bachelor of Science degree in Chemistry from Southern Methodist University in Dallas, TX.  He also has an M.B.A. in Finance from Butler University. Bryan H. King, M.D. (SAB)    Dr. King is Professor and Vice Chair of Psychiatry and Behavioral Sciences and Director of Child and Adolescent Psychiatry at the University of Washington and Seattle Children’s Hospital. Dr. King’s clinical and research interests have been focused on  psychiatric aspects of developmental disorders, repetitive movements,  and upon the pathogenesis and treatment of behavioral disturbance in  autism. He currently chairs a multi-site psychopharmacology network for the  National Institutes of Health funded STAART (Studies to Advance Autism  Research and Treatment) Centers formed to examine the potential role for  an antidepressant medication in the treatment of children with autism  who have significant problems with repetitive behaviors. He is also Director of the NIH funded UW Autism Center of Excellence and the Seattle Children’s Autism Center.      Dr. King completed his medical training at the Medical College of Wisconsin, and subsequently did his medical internship and psychiatric training at the UCLA Medical Center and Neuropsychiatric Institute. He obtained his clinical and research training in Child and Adolescent Psychiatry at UCLA and at the Merck Neuroscience Research Center in England with sponsorship of the National Institutes of Health.  Dr. King is a co-author on the practice parameters for children and adults with developmental disorders and mental illnesses by the American Academy of Child and Adolescent Psychiatry. He has written extensively in the medical literature relating to this field, and has received lifetime achievement awards from the American Academy of Child and Adolescent Psychiatry, and from the American Psychiatric Association, for his work in the field of Developmental Disabilities. Joseph Muldoon  (BAB) Chief Executive Officer & Board Director- FAST BioMedical                    Mr. Muldoon leverages decades of experience, from technology start-ups to publicly-traded multi-nationals. He has worked with dozens of entrepreneurial companies with roles spanning advisor, investor, and CEO as an Entrepreneur in Residence of the Indiana Venture Center.  His focus is enterprise value creation, culture building and mergers, acquisitions, and exits.  His medical technology experience includes TGX Medical, Vasc-Alert, DynoMed (sold to ChartLogic) Trust Bearer Labs (sold to Verisign), and Geist Pharmaceuticals.  Previously, he was President and CEO of FirstMile Technologies, a start-up broadband provider he led through its sale.  Prior to that, he served as President of Brightpoint North America, a publicly traded Fortune 500 wireless company that grew                     fourfold to $750MM under his leadership. He has also held executive management positions at MacMillan.  He started his career as a CPA in Ernst & Young’s Entrepreneurial Services practice.  Mr. Muldoon has a Bachelor of Science in Business from Indiana University’s Kelley School of Business, where he is a panelist and speaker for multiple MBA programs    Legal, Regulatory and Other Collaborators     Confluence has retained the services of the following professionals to assist in the Company’s legal, regulatory and other affairs.     Mr. Marcus B. Chandler & Martin Zivitz (Legal Advisors)Attorney-at-LawBarnes & Thornburg, LLP11 South Meridian StreetIndianapolis, IN  46204-3535    Mr. Kenneth V. Phelps (Regulatory Advisor)President & CEOCamargo Pharmaceutical Services, LLC9825 Kenwood Road , Suite 203Cincinnati, OH  45242    Mr. David Nelson, PhD (NeuroPharmacology- Discovery & Development)Founder, Council Mountain Pharma ConsultingPhoenix, AZ 



Create a free website

			Powered by 




















✕















 





Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft
















Confluence Pharmaceuticals LLC in Indianapolis, IN | 351 W 10th St, Ste 528, Indianapolis, IN






< Back to previousConfluence Pharmaceuticals LLC(0){{slogan}}351 W 10th St, Ste 528Indianapolis, IN 46202{{yextOffer}}{{yextOffer}} {{phone[0]}}{{ctatag}}{{ctatag}}{{ctatag}}{{ctatag}}{{ctatag}} Add Photo Add PhotoAdd PhotoAdd Photo Website Email BusinessView MenuOrder NowBook a Reservation{{hotel_tag}}{{flowers_tag}}{{cars_tag}}{{circular_flyer_tag}}Buy a Gift Certificate{{rest_res_tag}}{{rest_profile_tag}}{{coupon_flyer_tag}}View yellow pages ad {{y}}{{ad.display_text}}{{r.review_text}}...ReviewsPhotosCouponsDetails{{phone[0]}}Powered by  Get DirectionsMore {{rank1catcity}}{{a.name}}({{a.rating.count}}){{a.slogan}}{{a.address}}  View More {{rank1cat}}Are You The Business Owner? Claim your free business listing on Superpages.com  and add important information about your business online. The more reviews and additional information you provide about your business, the easier it will be for customers to find you online.Claim This BusinessREVIEWSWrite a Review  My Ratings & Reviews Write a ReviewBusiness Owner Response,{{review_date(r.date)}}{{r.text.substr(0, 235)}}{{r.text.substr(235)}}... More Less{{r.signature}}{{r.signature}}{{r.signature}},{{review_date(r.date)}} Superpages.com EmployeeProvided by Citysearch.comProvided by Citysearch.com{{r.text.substr(0, 1000)}}{{r.text.substr(1000)}}... More LessWas this review helpful?Yes({{r.helpful_yes}})No({{r.helpful_total - r.helpful_yes}})|Business Owner Reply|Flag AbuseShowing {{pager.showingStart}}- {{pager.showingEnd}} of {{pager.showingTotal}} reviewsFirstPrev{{n}}NextLastPHOTOSView All Photos Add Photo Add PhotoVIDEOCOUPONS{{coupon.title}}Expires: {{coupon.expires}}DETAILSSuggest and UpdateDo you own this business?Message from {{profile.name}}... Read more LessProvided by CitySearchThis business is a Superpages advertiser.SocialCategories{{c.name}}, {{c.name}}, Additional Contacts{{phone}}Alt{{phone}}Fax{{phone}}FreeIn Business Since2010... More2010 LessWebsiteView Menu More DetailsThe person icon  Employee Image indicates that the reviewer is an employee of Dex Media, Inc. Dex Media operates and sells advertising on Superpages.com. The views expressed in reviews are the opinion of each respective reviewer and do not necessarily reflect the view of Dex Media.Data provided by one or more of the following: Dex Media, Acxiom, Infogroup, Yext, Pingup.




Confluence Pharmaceuticals LLC                                                                                           - Carmel                                            , IN         - Company Information









 



























Products
Resources
My Account












Talk to a D&B Advisor 
1-800-280-0780 




Business Directory



IN



Carmel



Drugs, Proprietaries, and Sundries



Pharmaceuticals



                            Confluence Pharmaceuticals LLC
                                    



 





















C 


Confluence Pharmaceuticals LLC                                                                                          
CLAIM THIS BUSINESS



4904 DEER RIDGE DR S CARMEL, IN 46033
Get Directions



(317) 379-7498
 





Business Info



 Founded 2010
 Incorporated IN
 Annual Revenue $105,249.00
 Employee Count 2
 Industries Pharmaceuticals
 Contacts Boyd W Sturdevant Jr                                                                                                    







Contact Business







Your Email Address

Subject:


Message


Send Message





Company Summary


Confluence Pharmaceuticals Llc                                                                                           is located at 4904 Deer Ridge Dr S in Carmel and has been in the business of Pharmaceuticals since 2010. 









VERIFIED Status:
UNVERIFIED



Address:
UNVERIFIED





LAST VERIFIED:

                                    --
                                



Phone:

                                    UNVERIFIED
                                





Payment Method:
UNVERIFIED


view full report





Similar Businesses Nearby


                                        Our similar businesses nearby shows similar businesses in their industry and region based on information found in their Dun & Bradstreet Credibility Review profile.                                        







Competitive Landscape


                                        Our competitive landscape shows how this business compares to similar businesses in their industry and region based on information found in their Dun & Bradstreet Credibility Review profile.                                        







Payments Accepted

NO DATA



Hours



                                        Sunday 

                                        

                                                                                            --
                                            
                                        



                                        Monday 

                                        

                                                                                            --
                                            
                                        



                                        Tuesday 

                                        

                                                                                            --
                                            
                                        



                                        Wednesday 

                                        

                                                                                            --
                                            
                                        



                                        Thursday 

                                        

                                                                                            --
                                            
                                        



                                        Friday 

                                        

                                                                                            --
                                            
                                        



                                        Saturday 

                                        

                                                                                            --
                                            
                                        







C

VIEW ADDITIONAL DATA                        
Select from over 115 networks below to view available data about this business. If this data is unavailable or inaccurate and you own or represent this business, click here for more information on how you may be able to correct it. 







Credibility Review





Google





Facebook.com





Yellowbook.com





Bing.com





Yellowpages.com





MerchantCircle





Tele Atlas (TomTom)





Twitter.com





AOL





MapQuest





Yahoo Local





Apple/Siri





Groupon





Hotfrog.com





Comcast.net Search





ReachLocal





Admedia





Dealsplus





Shoptopia.com





Alteryx





Dogtime Media





KSL.com





Sirtune





AmericanTowns.com





Driverside





Kudzu.com





SpecialsAgent.com





Answers.com





eGood





LawInfo.com





spotlikes.com





anywho.com





eGumball





Likeness.com





Spotzot





eServiceLog





MapMyRun





TechnoCom





apartmentguide.com





ezlocal.com





EZToUse.com





Teleroute





AroundMe.com





metropolist.com





Therapists.com





Atlanta NewHomes





FindLaw.com





Time Out New York





Avantar





FindTheBest.com





mojopages.com





B2B Yellowpages





Fivestar Software





MyCityWay.com





TripAdvisor





bckyrd.com





GiftCards.com





MyCoupons.com





beachcalifornia.com





GoLocal247.com





mymove.com





UpMeSocial.com





Belo





GoodInfo





News-Gazette





Nokia





usdirectory.com





Cars.com





Nomao





Centzy.com





hibu





Openlist.com





ChaCha Search





Homeplate.com





OwnLocal.com





VisiKard





challama.com





Homestore





patch.com





Voltari





CityBot





Pelopidas





Vouchd





ClassifiedAds





Hostway





PlaceIQ





WalkScore.com





CloudMade





Hoodoyou





PlanetDiscover.com





WeddingWire.com





PowerProfiles





Where Inc.





Contractors.com





iGoLocal.com





Radiate Media





Wikiocity





CouponMap





Indeed.com





Wimgo.com





CrowdSpot





Innova Electronics





Intellistrand





realtor.com





DataSphere





InTheMO.com





Reply.com





Yellowbot.com





JiWire





Rocket Fuel





YellowPageCity.com





DMV.org





Justclicklocal.com





Dirxion





Keen.com





Zidster.com












Photos














































Business Credit Report
Receive a one-time comprehensive credit report on this company.
get full credit report


Facebook








Twitter








Yelp






































Call 1.800.280.0780 to speak with a D&B Advisor Today!







Customer Resources
Products
Education Center
Business Articles & Insights
Glossary
Contact Us
Customer Support
Communication Preferences
Search for D&B D-U-N-S




Our Company
About Us
Company History
Business Credit History
Careers
Press Releases
News
Success Stories
Hoovers




Our Network
Partners
Affiliates
Blog
Access to Capital
Entrepreneurial Initiative
D&B International
SupplierEdge




Site Links
Business Directory
Site Map
PIPEDA
Privacy Policy
Website Terms of Service
Product License Agreement







© Dun & Bradstreet, Inc. 2017. All rights reserved.

























 















Bing Places for Business
























































































































Bing
 places for business


Sign in using your




Microsoft Account





Work Account





Google Account





Facebook Account

Don't have an account? Create one.




Confluence Pharmaceuticals LLC: Company Profile - Bloomberg



































































  









Feedback























confluence pharmaceuticals llc
Private Company









Company Profile
Sector: Health Care
Industry: Health Care Facilities & Svcs
Sub-Industry: Health Care Services
Confluence Pharmaceuticals LLC provides health care services. The Company offers clinically-discovered therapeutic treatment for social and communication impairments caused by fragile x syndrome and autism spectrum disorders. Confluence Pharmaceuticals serves patients in the United States.




Corporate Information
Address:

351 West 10th Street
Box 528
Indianapolis, IN 46202
United States


Phone:
1-317-379-7498


Fax:
-


Web url:
www.confluencepharma.com























From The Web












Sponsored Financial Commentaries







More From The Web


















Home


News


Top Headlines
Most Popular
Exclusive
Law
Entrepreneurs
Leaders
Economy
Environment
Science
Sports
Markets Magazine
Pursuits Magazine
Bloomberg Visual Data
Bloomberg Best (and Worst)
For comments or complaints about news coverage click here


Regions
U.S.
China
Europe
Asia
U.K. & Ireland
Australia & New Zealand
Canada
India & Pakistan
Japan
Africa
Eastern Europe
Latin America
Middle East
Markets
Commodities
Currencies
Bonds
Stocks
Energy Markets
Municipal Bonds
Emerging Markets
Funds
Islamic Finance
Industries
Energy
Technology
Real Estate
Finance
Health Care
Transportation
Insurance
Retail
Media
Manufacturing




Quick


Market Data


Stocks
Stock Futures
World Indexes
Americas
Europe, Middle East, & Africa
Asia-Pacific
Gainers & Losers
Earnings Calendar
Industry Leaders
Currencies
Americas
Europe, Middle East, & Africa
Asia-Pacific
Foreign Exchange Cross Rates
FX Fixings
Currency Converter
Forex Trading Videos
Commodities
Energy Prices
Metals Prices
Agricultural Prices


Rates & Bonds
US Treasuries
UK Gilts
Germany Bunds
Japan Bonds
Australia Bonds
Bloomberg Bond Indexes
Corporate Bonds
Consumer Rates
Economic Calendar
Watchlist
European Debt Crisis
Symbol Search
The Market Now




Personal Finance


Top Headlines
Saving & Investing
Real Estate
Retirement Planning
Financial Advisers
Taxes
Blog: Ventured & Gained
Real Cost Of
Money Gallery
Calculators
Watchlist (Portfolio Tracker)




Tech


Top Headlines
Social Media
Mobile & Wireless
Web
Enterprise Tech
TV, Games & Movies
Apple
Tech Deals
Global Tech
Slideshows
Videos




U.S. Politics


Sustainability


Top Headlines
Energy
Corporate Sustainability
Policy
Natural Resources
Health & Population
Slideshows
Videos
Blog: The Grid




Luxury


Top Headlines
Autos
Billionaires
Living
Property
Travel
Well Spent
Loot Blog
Pursuits Magazine
Videos




TV


Live TV
Channel Finder
Personalities
Apple TV
iPad App
Schedule
U.S.
Asia
Europe


Shows
Surveillance
Market Makers
Lunch Money
Street Smart
Bloomberg West
Game Changers




Video


Must See
Latest
Live TV
Shows
Playlist




Radio


Live Radio
Shows
Schedule
Personalities
Podcasts
Bloomberg Brief
Featured Podcasts and New Shows
Bloomberg View
Masters in Business
First Word
Surveillance
Bloomberg Advantage
In the Loop
Bloomberg Law
Taking Stock
Bloomberg Best
More Podcasts




Blogs


Global Tech
The Grid
Loot
The Market Now
Political Capital
Tech Deals
Ventured and Gained




Opinion




My Saved



Registration



Sign In



Bloomberg.com



Businessweek.com



Company



About
Blog
Careers
Diversity & Inclusion
News Mission
Philanthropy & Engagement
Press Room
Procurement
Sustainability




Products



Financial Products
Bloomberg Professional Service
Bloomberg Anywhere
Bloomberg Tradebook
Bloomberg Briefs
Bloomberg Indexes
Bloomberg SEF
Service Center
Customer Support
Enterprise Products
Enterprise Solutions
Trading Solutions
Industry Products
Bloomberg BNA
Bloomberg Government
Bloomberg Law
Bloomberg Link
Bloomberg New Energy Finance
Bloomberg Sports
Content Licensing




Bloomberg Anywhere



Mobile Apps



Bloomberg Visual Data



































Confluence Pharmaceuticals | AngelList

































































Join
 
Log In







AngelList


Startup Jobs

Recruit

Invest

More





Companies

Freelancers

Incubators

Track

Salaries
Valuations

Help











Your Alumni Network








Companies

Freelancers

Incubators

Track

Salaries
Valuations

Help



















 


Confluence Pharmaceuticals is on AngelList, where the world meets startups.

To connect with Confluence Pharmaceuticals,
sign up
for AngelList today.





Sign up
Log in


















Confluence Pharmaceuticals


Novel, patented Autism & Fragile X Drug Discovery




Share





















Indianapolis







Neuroscience · Therapeutics · Biotechnology · Life Sciences







employees


















confluencepharma.com







Sign up to see how you are connected to Confluence Pharmaceuticals






















Confluence Pharmaceuticals







Share









Company







Overview



Overview








There was a problem loading your content.



Product

























































Confluence Pharmaceuticals is the exclusive licensee of aclinically discovered, novel therapeutic treatment for core social and communication impairments in individuals suffering from Autism Spectrum Disorders (ASD) and Fragile X Syndrome (FXS). There is no FDA approved medication for these life-long impairments. According to published studies, the potential success of a therapeutic drug could… · More reduce the cost of life-long care by as much as two-thirds.






Founders







Steve Johns


Co-Founder of @confluence-pharmaceuticals-2
former CEO of @Egix, Inc.
former CEO of ENS, Inc.
former Managing Member of DSL Indiana Acquisitions LLC








Boyd W. Sturdevant, Jr.


Chairman and Founder of @Confluence Pharmaceuticals LLC








Craig Erickson


Founder & Lead Scientific Advisor.  MD Psychiatry, Chief -Christian Sarkine Autism Center and Fragile X Research & Treatment Center, IU School of Medicine







Funding


Investors
from previous rounds







Steve Johns


Unmet need market, Orphan Drug candidate, has significant human data in disease states.








Boyd W. Sturdevant, Jr.


Chairman and Founder of @Confluence Pharmaceuticals LLC








Craig Erickson


Founder & Lead Scientific Advisor.  MD Psychiatry, Chief -Christian Sarkine Autism Center and Fragile X Research & Treatment Center, IU School of Medicine







Team



Advisors







Tim Parshall


Director at Pivotal Strategies LLC and Biotechnology Consultant








Joe Muldoon


Board member at @Confluence Pharmaceuticals LLC








Bradley Fravel


Business Development Manager at the Indiana University Research & Technology Corporation.  PhD Chemistry, MBA Finance







Jobs

Confluence Pharmaceuticals
hasn't added any jobs yet.







Notification Set





Get Notified







Which position are you applying for?






Add a message to Confluence Pharmaceuticals



Apply










Notify Me When Confluence Pharmaceuticals Lists Jobs








Create Notification









See Similar Jobs



View jobs page




People also viewed



ImStar Therapeutics
Transforming ALS & Neurodegenerative...





Verge Genomics
Faster cures using genomics (YC S15)





Neurogenica
Systems Biology and genomics let us...





Halo Neuroscience
Neuroscience-based technology for...





Optempus Medical
Better surgical tools





Cerora
Device & Software Platform for Brain...





Cambridge Bio-Augmentation Systems
Plug & Play Bionic Devices





EnteroWave
Minimally Invasive Neurostimulators...














Help
·
Directory
·
Blog
Twitter
·
Terms & Risks
·
Unsubscribe

·
Mobile



·
Desktop


·

Profile not verified







